Anthem Biosciences Stock Price Today – Performance, News & Forecast
Anthem Biosciences Stock
Explore Anthem Biosciences stock price, performance trends, and future forecast for 2025. Get key insights, expert analysis, and latest market news.
Introduction: Why Investors Are Watching Anthem Biosciences Stock in 2025
In the dynamic world of biotech investments, Anthem Biosciences stock is catching the attention of both retail and institutional investors. Known for its strong foothold in contract research and manufacturing services (CRAMS), Anthem Biosciences has been a rising player in India’s pharmaceutical sector.
With IPO speculations, solid financial growth, and expansion plans underway, this article aims to break down the current stock price trends, financial performance, recent company news, and what the future holds for investors. Whether you’re a long-term investor or just exploring biotech opportunities, this guide offers the insights you need.
1. Anthem Biosciences Stock Price Overview
Though Anthem Biosciences is not yet publicly listed, there’s increasing market chatter around its potential IPO. The company has shown consistent financial strength, which has built strong investor confidence even before its official listing.
However, private share transactions in the grey market and unlisted share platforms suggest a price range of ₹750–₹850 per share as of July 2025. This valuation is based on investor interest, projected earnings, and comparison with similar companies in the biotech space.
📊 Statistic: In 2024, Anthem Biosciences recorded over ₹1,000 crore in revenue, with a 25% YoY growth rate, making it one of the most promising unlisted biotech firms in India.
2. Company Background & Financial Performance
Anthem Biosciences was founded in 2007 and is headquartered in Bengaluru. The company specializes in:
- Contract research and development
- Custom synthesis and manufacturing
- Analytical testing
- Biopharmaceutical services
Over the past 5 years, Anthem has grown its infrastructure, expanded R&D facilities, and partnered with global pharmaceutical giants.
Key Financial Highlights:
- FY 2022–23 Revenue: ₹950 crore
- FY 2023–24 Revenue: ₹1,200 crore
- EBITDA Margin: Approx. 28%
- Net Profit (FY 2023–24): ₹230 crore
💡 These strong margins reflect Anthem’s asset-light model and focus on high-value services in the life sciences sector.
3. Latest News: IPO Buzz & Expansion Plans
One of the biggest drivers of investor interest in Anthem Biosciences stock is the upcoming IPO. According to multiple reports, the company is planning to file its Draft Red Herring Prospectus (DRHP) by Q4 2025.
Additionally, Anthem recently announced a ₹400 crore investment to expand its R&D facility in Bengaluru and set up a new biologics manufacturing unit. This move is expected to double its production capacity by 2026.
Recent Developments:
- Acquired a 60-acre plot near Hyderabad for biologics plant
- Strengthened partnerships with U.S. and European pharma companies
- Expected IPO valuation: ₹8,000–₹10,000 crore
📈 Statistic: Anthem Biosciences was ranked among the Top 10 CRAMS companies in India by BioSpectrum in 2024.
4. Investment Potential: Is Anthem a Smart Bet?
While investing in unlisted shares carries higher risks, Anthem Biosciences’ performance and sector outlook make it an attractive pre-IPO bet for seasoned investors.
Reasons to Consider Investing:
- Strong growth trajectory and financials
- Sectoral demand for biotech & CRAMS services
- Upcoming IPO could deliver listing gains
- Consistent profitability and client retention
Risks to Consider:
- Lack of liquidity in unlisted shares
- No guarantee on IPO timeline or valuation
- Regulatory risks in the pharmaceutical industry
5. Case Study: Early Investor Success Story
Rajeev Sharma, a Bengaluru-based investor, purchased Anthem shares in 2022 through an unlisted share platform at ₹450/share. With current grey market rates hovering around ₹800, his investment has nearly doubled in value in 3 years.
Rajeev says:
“I invested based on the company’s revenue performance and the buzz around CRAMS. The upcoming IPO could further boost my returns.”
His story is one of many that highlight the potential of early investing in promising biotech firms like Anthem.
Conclusion: Anthem Biosciences Stock – Worth the Hype?
With its impressive performance, consistent revenue growth, and imminent IPO plans, Anthem Biosciences stock is deinitely one to watch in 2025. While it’s still unlisted, savvy investors are already positioning themselves for long-term gains. However, as with all pre-IPO investments, due diligence is essential.
👉 Call to Action:
Stay updated with Anthem’s IPO timeline and financials. If you’re considering unlisted investments, consult a registered advisor and track Anthem Biosciences on platforms like NSDL and unlisted market aggregators.
